William Blair Thinks Spark Therapeutics’ Stock is Going to Recover


In a report released today, Raju Prasad from William Blair maintained a Buy rating on Spark Therapeutics (ONCE). The company’s shares closed on Friday at $42.13, close to its 52-week low of $35.63.

According to TipRanks.com, Prasad is a 1-star analyst with an average return of -4.1% and a 28.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Logicbio Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spark Therapeutics with a $62.18 average price target, implying a 47.6% upside from current levels. In a report issued on November 26, Raymond James also maintained a Buy rating on the stock.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $96.59 and a one-year low of $35.63. Currently, Spark Therapeutics has an average volume of 574.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts